📊 TTRX Key Takeaways
Is Turn Therapeutics Inc. (TTRX) a Good Investment?
Turn Therapeutics is a pre-revenue pharmaceutical company with severe liquidity constraints and limited runway. With only $4.0M in cash and negative operating cash flow of -$2.6M annually, the company faces critical funding pressure within approximately 18 months. Financial metrics deteriorated sharply (net income down 80.6% YoY) with a current ratio of 0.87x indicating current liabilities exceed current assets.
Why Buy Turn Therapeutics Inc. Stock? TTRX Key Strengths
- Zero debt outstanding eliminates leverage and bankruptcy risk from leverage
- Remaining cash reserves of $4.0M provide near-term operational buffer
- Insider activity (5 Form 4 filings in 90 days) indicates management engagement
TTRX Stock Risks: Turn Therapeutics Inc. Investment Risks
- No revenue generation; company remains in pre-revenue stage with no commercial products
- Negative operating cash flow of -$2.6M with only 18-month runway at current burn rate
- Liquidity crisis: current ratio of 0.87x means current liabilities exceed current assets
- Net income deteriorated 80.6% year-over-year indicating accelerating losses
- Minimal asset base ($12.2M total) provides limited financial flexibility
Key Metrics to Watch
- Monthly operating cash burn rate and remaining cash runway
- Clinical trial outcomes and regulatory milestone achievements
- Equity fundraising announcements and dilution impact
Turn Therapeutics Inc. (TTRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
TTRX Profit Margin, ROE & Profitability Analysis
TTRX vs Healthcare Sector: How Turn Therapeutics Inc. Compares
How Turn Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Turn Therapeutics Inc. Stock Overvalued? TTRX Valuation Analysis 2026
Based on fundamental analysis, Turn Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Turn Therapeutics Inc. Balance Sheet: TTRX Debt, Cash & Liquidity
TTRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Turn Therapeutics Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.07 indicates the company is currently unprofitable.
TTRX Revenue Growth, EPS Growth & YoY Performance
Turn Therapeutics Inc. Dividends, Buybacks & Capital Allocation
TTRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Turn Therapeutics Inc. (CIK: 0002023016)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TTRX
What is the AI rating for TTRX?
Turn Therapeutics Inc. (TTRX) has an AI rating of STRONG SELL with 80% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TTRX's key strengths?
Claude: Zero debt outstanding eliminates leverage and bankruptcy risk from leverage. Remaining cash reserves of $4.0M provide near-term operational buffer.
What are the risks of investing in TTRX?
Claude: No revenue generation; company remains in pre-revenue stage with no commercial products. Negative operating cash flow of -$2.6M with only 18-month runway at current burn rate.
What is TTRX's revenue and growth?
Turn Therapeutics Inc. reported revenue of N/A.
Does TTRX pay dividends?
Turn Therapeutics Inc. does not currently pay dividends.
Where can I find TTRX SEC filings?
Official SEC filings for Turn Therapeutics Inc. (CIK: 0002023016) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TTRX's EPS?
Turn Therapeutics Inc. has a diluted EPS of $-0.12.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TTRX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Turn Therapeutics Inc. has a STRONG SELL rating with 80% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TTRX stock overvalued or undervalued?
Valuation metrics for TTRX: ROE of -68.2% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TTRX stock in 2026?
Our dual AI analysis gives Turn Therapeutics Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TTRX's free cash flow?
Turn Therapeutics Inc.'s operating cash flow is $-2.6M, with capital expenditures of N/A.
How does TTRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -68.2% (avg: 15%), current ratio 0.87 (avg: 2).